Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer with Elevated CA125
NCT04835064Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
01
Overview
A Phase 3 trial of paclitaxel, gemcitabine, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University. Status: unknown.
02
Drugs
paclitaxelgemcitabineoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04835064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835064.